Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 17/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.47 |
| ▸ | PDE4A | P27815 | 12/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7802776 | 0.96 | PDE4D (0.44) | PDE4DPDE4BPDE4APDE4CCYP1A2 | |
| SCHEMBL7798523 | 0.96 | PDE4D (0.44) | PDE4DPDE4BPDE4APDE4CCYP1A2 | |
| SCHEMBL7792939 | 0.95 | PDE4D (0.43) | PDE4DPDE4BPDE4APDE4CCYP1A2 | |
| SCHEMBL7802772 | 0.95 | PDE4D (0.43) | PDE4DPDE4BPDE4APDE4CCYP1A2 | |
| SCHEMBL7800730 | 0.94 | PDE4D (0.43) | PDE4DPDE4BPDE4APDE4CCYP1A2 | |
| SCHEMBL7800667 | 0.94 | PDE4D (0.42) | PDE4DPDE4BPDE4APDE4CCYP1A2 | |
| SCHEMBL7800704 | 0.94 | PDE4D (0.42) | PDE4DPDE4BPDE4APDE4CCYP1A2 | |
| SCHEMBL7799057 | 0.93 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7802756 | 0.92 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CIDO1 | |
| SCHEMBL7793201 | 0.92 | PDE4D (0.51) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | claimed |
| EP-1435958-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GmbH (DE) | 2004-07-14 | — | — | EP | claimed |
| WO-2003032993-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | WO | claimed |
| EP-0723962-B1 | Arylalkyl-thiadiazinones | MERCK PATENT GMBH (DE) | 2001-07-04 | — | — | EP | claimed |
| US-6025354-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-02-15 | — | — | US | claimed |
| US-5747489-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-05-05 | — | — | US | claimed |
| EP-0723962-A1 | Arylalkyl-thiadiazinones | MERCK PATENT GmbH (DE) | 1996-07-31 | — | — | EP | claimed |
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1435958-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GmbH (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032993-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | WO | disclosed |
| EP-0723962-B1 | Arylalkyl-thiadiazinones | MERCK PATENT GMBH (DE) | 2001-07-04 | — | — | EP | disclosed |
| US-6025354-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-02-15 | — | — | US | disclosed |
| US-5747489-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-05-05 | — | — | US | disclosed |
| EP-0723962-A1 | Arylalkyl-thiadiazinones | MERCK PATENT GmbH (DE) | 1996-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | PDE4D 12/4885PDE4B 4/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.